What is Cellular Reprogramming? [A Gentle Explanation: The Current State of Technology to 'Rejuvenate' Cells]

Last updated: June 2026 / Supervised by: WSN. We Do Not Die. Editorial Department

■ 1. What is Reprogramming?

Our bodies are made of cells with different roles, such as skin, liver, and nerves, but if you trace them back, they all originated from a single fertilized egg. It was long believed that as cells grew, they learned their roles—'I am skin,' 'I am liver'—and could never return to being other types of cells.

Dr. Shinya Yamanaka overturned this. In 2006, he demonstrated that by introducing just four genes (Yamanaka factors: Oct4, Sox2, Klf4, and c-Myc), adult cells could be rewound to an 'initial state capable of becoming anything (iPS cells).' He received the 2012 Nobel Prize in Physiology or Medicine for this achievement. In other words, cells had a switch to 'rewrite their resumes.' Reprogramming is the technology that uses this switch to reshape the state of a cell.

■ 2. Why is 'Partial' the Key?

This is the most important point. If the Yamanaka factors are fully activated, cells forget their roles and return to their initial state. If this happens inside the body, there is a risk that cells will proliferate uncontrollably and become cancerous (teratomas). This has long been the biggest barrier to 'rejuvenation technology.'

This led to the idea of 'partial reprogramming.' The concept is to flip the switch for a short time and at a lower intensity, so that the cell's identity (e.g., a liver cell remains a liver cell) is preserved, while only the settings disrupted by aging (epigenetic markers) are returned to a slightly younger state. It is like 'restoring to a previous, well-functioning setting' rather than 'initializing to factory settings.'

■ 3. How is it Delivered into the Body?

There are mainly two ways to deliver the switch (factors) to cells in the body. One is gene therapy (using a harmless virus carrier called AAV) to deliver the blueprints for the factors. The other is using mRNA + lipid nanoparticles (LNP), which were also used in COVID-19 vaccines, to temporarily deliver instructions for creating the factors. The latter, which can be activated temporarily and then stopped, is considered easier to manage for safety.

■ 4. How Far Have We Come? (Current Status)

・Promising results in mice: There are reports of periodic partial reprogramming showing rejuvenation and life extension in progeria mice (Ocampo et al., 2016), and reports of restoring vision by rejuvenating the optic nerves of aged mice (Lu et al. / Professor Sinclair et al., 2020)
・Just at the entrance for humans: In 2026, Life Biosciences' ER-100 (delivering Oct4, Sox2, and Klf4 via AAV) entered the world's first human clinical trial for partial reprogramming. The target is initially optic nerve diseases
・Companies with massive funding are competing: Altos Labs (funded by Bezos and others), Retro Biosciences (funded by Sam Altman), NewLimit (Coinbase CEO), and others are advancing through preclinical to clinical preparation

■ 5. Expectations and Limitations (Let's be calm here)

The expectation is that it may not just 'treat aging symptom by symptom,' but could potentially work at the root by rewinding the clock at the cellular level. Practical application is expected to proceed from specific organs such as the eyes and liver.

On the other hand, the limitations are clear. There is no evidence yet that it has rejuvenated the entire human body or extended lifespan. Even at the cutting edge, it is at the stage of 'entering human clinical trials for specific diseases.' And the biggest challenge remains the management of cancer risk; the line drawn for 'how far back is safe' will determine the success or failure of this technology. It is appropriate to watch with awareness of the distance between mice and humans, without excessive expectations or outright denial.

Furthermore, even if liver reprogramming is successful, what is gained is an improvement in function, such as 'cells becoming easier to work like they did when young' or 'becoming more resistant to damage,' not that the organ will never break down again. Partial reprogramming rewinds the cellular clock slightly, and since it will age again afterward, repeated intervention is a prerequisite for maintenance. Development companies are not claiming 'immortality.' The original article provides a more detailed breakdown of frequently asked questions and the trends of each company.

──────────
For those who want to read more, please see the original article on WSN (We Do Not Die.).
Charts, the latest updates, and more detailed explanations can be found in the original.
▶ Original article: https://wsndb.com/articles/cellular-reprogramming-basics
▶ Site top: https://wsndb.com